Pharmaceutical composition containing clopidogrel and carbazochrome sodium sulfonate

Abstract

The invention provides a pharmaceutical composition containing active carbazochrome sodium sulfonate and clopidogrel or the pharmacologically acceptable salt thereof. The invention aims to invent a more effective and low adverse-reaction method for curing thrombotic diseases by using the combined medication of the carbazochrome sodium sulfonate and the clopidogrel. After conscientious trail of the patent applicant for many times, the effect of applying the carbazochrome sodium sulfonate to inhibit the thrombosis in a combined manner is discovered unexpected in the process of applying the clopidogrel to cure the thrombotic diseases, the anticoagulant effect of the clopidogrel is not abated but increased, and the very good synergistic effects are achieved after the combination of the carbazochrome sodium sulfonate and the clopidogrel, therefore, the risk of bleeding is greatly reduced when the advantages of good anticoagulant activity and fast effect of the clopidogrel during the antiplatelet aggregation are fully exerted, the risk of bleeding caused by the clopidogrel is greatly reduced and the compliance of patients is enhanced.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition, in particular to a pharmaceutical composition containing clopidogrel or a pharmacologically acceptable salt thereof and sodium carbosulfonate as active components. Background technique [0002] Sodium carbosulfonate (Xinanluoxue) is a new generation of hemostatic drug. It is a derivative of Anluoxue. The sodium sulfonate group is introduced into the molecular structure to overcome the low solubility of Anluoxue, which must be assisted by salicylic acid. The disadvantage of dissolving, thus avoiding the salicylic acid reaction that may occur after long-term repeated application. Compared with Anluoxue (adrenochrome hydrazone), sodium carbosulfonate has high water solubility, multiple routes of administration (oral, intramuscular or intravenous injection, intravenous infusion, endoscopic spraying, etc.), and has a fast hemostatic effect. Less adverse reactions, wide range of application, etc., s...

AI Technical Summary

Problems solved by technology

[0004] However, while clopidogrel has been widely used clinically and achieved good curative effect, its adverse reactions of bleeding have also attracted increasing attention. International experts have reached a consensus that "the more effective the antiplatelet agent is, the easier it is to cause bleeding". Contradictory, clopidogrel has strong anticoagulant activity, is effective in inhibiting platelet aggregation, and acts quickly, but it inevitably leads to an increased risk of bleeding

If the drug induces an increased risk of bleeding, even if the bleeding is not severe, it will significantly reduce the patient's compliance. The risk of reduced compliance is important in antiplatelet agents, which may lead to rebound cardiovascular events

Images